Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube®: a randomized clinical trial.

Gomes PJ, Abelson MB, Stein L, Viirre E, Villafranca JE, Lasser EC.

J Asthma Allergy. 2019 Mar 1;12:71-81. doi: 10.2147/JAA.S150251. eCollection 2019.

2.

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.

Malhotra RP, Meier E, Torkildsen G, Gomes PJ, Jasek MC.

Clin Ophthalmol. 2019 Feb 19;13:403-413. doi: 10.2147/OPTH.S186092. eCollection 2019.

3.
4.

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.

Cavet ME, Gomes PJ, Carr WW, Williams JI.

J Asthma Allergy. 2018 Mar 23;11:29-39. doi: 10.2147/JAA.S160687. eCollection 2018.

5.

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.

McLaurin E, Cavet ME, Gomes PJ, Ciolino JB.

Optom Vis Sci. 2018 Mar;95(3):264-271. doi: 10.1097/OPX.0000000000001182.

6.

Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness.

Torkildsen GL, Sanfilippo CM, DeCory HH, Gomes PJ.

Curr Eye Res. 2018 Jan;43(1):43-51. doi: 10.1080/02713683.2017.1381269. Epub 2017 Nov 9.

PMID:
29120262
7.

Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model.

Torkildsen G, Abelson MB, Gomes PJ, McLaurin E, Potts SL, Mah FS.

J Ocul Pharmacol Ther. 2017 Mar;33(2):79-90. doi: 10.1089/jop.2016.0154. Epub 2017 Jan 10.

PMID:
28072552
8.

Technical and clinical validation of an environmental exposure unit for ragweed.

Gomes PJ, Lane KJ, Angjeli E, Stein L, Abelson MB.

J Asthma Allergy. 2016 Dec 14;9:215-221. doi: 10.2147/JAA.S123547. eCollection 2016.

9.

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management.

Ackerman S, Smith LM, Gomes PJ.

Ther Adv Chronic Dis. 2016 Jan;7(1):52-67. doi: 10.1177/2040622315612745. Review.

10.

Radiation damage on Langmuir monolayers of the anionic 1.2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt)(DPPG) phospholipid at the air-DNA solution interface.

Gomes PJ, Gonçalves da Silva AM, Ribeiro PA, Oliveira ON Jr, Raposo M.

Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:576-9. doi: 10.1016/j.msec.2015.09.017. Epub 2015 Sep 7.

PMID:
26478346
11.

Energy Thresholds of DNA Damage Induced by UV Radiation: An XPS Study.

Gomes PJ, Ferraria AM, Botelho do Rego AM, Hoffmann SV, Ribeiro PA, Raposo M.

J Phys Chem B. 2015 Apr 30;119(17):5404-11. doi: 10.1021/acs.jpcb.5b01439. Epub 2015 Apr 16.

PMID:
25844940
12.

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%.

Bergmann MT, Williams JI, Gomes PJ.

Clin Ophthalmol. 2014 Aug 13;8:1495-505. doi: 10.2147/OPTH.S66637. eCollection 2014.

13.

Trends in prevalence and treatment of ocular allergy.

Gomes PJ.

Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):451-6. doi: 10.1097/ACI.0000000000000100. Review.

PMID:
25115683
14.

DNA damage induced by carbon ions (C³⁺) beam accessed by independent component analysis of infrared spectra.

Raposo M, Coelho M, Gomes PJ, Vieira P, Ribeiro PA, Mason NJ, Hunniford CA, McCullough RW.

Int J Radiat Biol. 2014 May;90(5):344-50. doi: 10.3109/09553002.2014.892650. Epub 2014 Mar 20.

PMID:
24517474
15.

Characterization of PAH/DPPG layer-by-layer films by VUV spectroscopy.

Duarte AA, Gomes PJ, Ribeiro JH, Ribeiro PA, Hoffmann SV, Mason NJ, Oliveira ON Jr, Raposo M.

Eur Phys J E Soft Matter. 2013 Sep;36(9):98. doi: 10.1140/epje/i2013-13098-7. Epub 2013 Sep 5.

PMID:
24008406
16.

Mathematica program: its use to simulate metabolic irreversible pathways and inhibition of the first enzyme of a pathway by its end product as visualized with the reservoir model.

López-Cánovas F, Gomes PJ, Sillero A.

Comput Biol Med. 2013 Aug 1;43(7):853-64. doi: 10.1016/j.compbiomed.2013.04.003. Epub 2013 Apr 18.

PMID:
23746727
17.

Adsorption kinetics of DPPG liposome layers: a quantitative analysis of surface roughness.

Duarte AA, Filipe SL, Abegão LM, Gomes PJ, Ribeiro PA, Raposo M.

Microsc Microanal. 2013 Aug;19(4):867-75. doi: 10.1017/S1431927613001621. Epub 2013 Jun 7.

PMID:
23742922
18.

Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy.

Gomes PJ, Ousler GW, Welch DL, Smith LM, Coderre J, Abelson MB.

Clin Ophthalmol. 2013;7:157-65. doi: 10.2147/OPTH.S38732. Epub 2013 Jan 20.

19.

Determination of degree of ionization of poly(allylamine hydrochloride) (PAH) and poly[1-[4-(3-carboxy-4 hydroxyphenylazo)benzene sulfonamido]-1,2-ethanediyl, sodium salt] (PAZO) in layer-by-layer films using vacuum photoabsorption spectroscopy.

Ferreira Q, Gomes PJ, Ribeiro PA, Jones NC, Hoffmann SV, Mason NJ, Oliveira ON Jr, Raposo M.

Langmuir. 2013 Jan 8;29(1):448-55. doi: 10.1021/la304036h. Epub 2012 Dec 26.

PMID:
23215445
20.

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.

Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI; Bepotastine Besilate Ophthalmic Solutions Study Group.

Allergy Asthma Proc. 2012 May-Jun;33(3):265-74.

PMID:
22991696
21.

Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.

Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Study Group.

J Ocul Pharmacol Ther. 2011 Aug;27(4):385-93. doi: 10.1089/jop.2011.0005. Epub 2011 Jun 7.

PMID:
21649522
22.

Antihistamines in ocular allergy: are they all created equal?

Abelson MB, McLaughlin JT, Gomes PJ.

Curr Allergy Asthma Rep. 2011 Jun;11(3):205-11. doi: 10.1007/s11882-011-0188-5. Review.

PMID:
21437647
23.

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.

Torkildsen GL, Williams JI, Gow JA, Gomes PJ, Abelson MB, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Ann Allergy Asthma Immunol. 2010 Jul;105(1):57-64. doi: 10.1016/j.anai.2010.04.005.

PMID:
20642205
24.

Polymeric scaffolds for enhanced stability of melanin incorporated in liposomes.

Moraes ML, Gomes PJ, Ribeiro PA, Vieira P, Freitas AA, Köhler R, Oliveira ON Jr, Raposo M.

J Colloid Interface Sci. 2010 Oct 1;350(1):268-74. doi: 10.1016/j.jcis.2010.06.043. Epub 2010 Jun 22.

PMID:
20633887
25.

Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.

Macejko TT, Bergmann MT, Williams JI, Gow JA, Gomes PJ, McNamara TR, Abelson MB; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Am J Ophthalmol. 2010 Jul;150(1):122-127.e5. doi: 10.1016/j.ajo.2010.02.007. Epub 2010 May 20.

PMID:
20488431
26.

Exothermic rate restrictions in long-range photoinduced charge separations in rigid media.

Gomes PJ, Serpa C, Nunes RM, Arnaut LG, Formosinho SJ.

J Phys Chem A. 2010 Mar 4;114(8):2778-87. doi: 10.1021/jp9108255. Erratum in: J Phys Chem A. 2010 Oct 7;114(39):10759-60.

PMID:
20136085
27.

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.

PMID:
19843481
28.

A highly reproducible continuous process for hydroxyapatite nanoparticles synthesis.

Gomes PJ, Silva VM, Quadros PA, Dias MM, Lopes JC.

J Nanosci Nanotechnol. 2009 Jun;9(6):3387-95.

PMID:
19504858
29.

A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.

Rosenwasser LJ, Mahr T, Abelson MB, Gomes PJ, Kennedy K.

Allergy Asthma Proc. 2008 Nov-Dec;29(6):644-53. doi: 10.2500/aap.2008.29.3176. Epub 2008 Dec 6.

PMID:
19063816
31.

Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.

Abelson MB, Gomes PJ.

Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):453-61. doi: 10.1517/17425255.4.4.453 . Review.

PMID:
18433347
32.

Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.

Abelson MB, Gomes PJ, Pasquine T, Edwards MR, Gross RD, Robertson SM.

Allergy Asthma Proc. 2007 Jul-Aug;28(4):427-33.

PMID:
17883910
33.

Influence of ionic interactions on the photoinduced birefringence of poly[1-[4-(3-carboxy-4 hydroxyphenylazo) benzene sulfonamido]-1,2-ethanediyl, sodium salt] films.

Ferreira Q, Gomes PJ, Raposo M, Giacometti JA, Oliveira ON Jr, Ribeiro PA.

J Nanosci Nanotechnol. 2007 Aug;7(8):2659-66.

PMID:
17685281
34.

Methodologies for the study of ocular surface disease.

Ousler GW, Gomes PJ, Welch D, Abelson MB.

Ocul Surf. 2005 Jul;3(3):143-54.

PMID:
17131019
35.

Temperature dependence of ultra-exothermic charge recombinations.

Serpa C, Gomes PJ, Arnaut LG, de Melo JS, Formosinho SJ.

Chemphyschem. 2006 Dec 11;7(12):2533-9.

PMID:
17072943
36.

Electron transfer in supercritical carbon dioxide: ultraexothermic charge recombination at the end of the "inverted region".

Serpa C, Gomes PJ, Arnaut LG, Formosinho SJ, Pina J, de Melo JS.

Chemistry. 2006 Jun 23;12(19):5014-23.

PMID:
16548016
37.

Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.

Berger W, Abelson MB, Gomes PJ, Beck M, Kimura S, Westbrook T, Storms W, Galant S.

Ann Allergy Asthma Immunol. 2005 Oct;95(4):361-71.

PMID:
16279567
38.

Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.

Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Turner FD, Wells DT, Robertson SM.

Curr Med Res Opin. 2005 May;21(5):683-91.

PMID:
15969867
39.

Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.

Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Gross RD, Turner FD, Wells DT, Bergamini MV, Robertson SM.

Clin Ther. 2004 Aug;26(8):1237-48.

PMID:
15476905
40.
41.

RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2.

Li H, Gomes PJ, Chen JD.

Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8479-84.

42.

Attempted preservation of one gonad in patients with bilateral germ cell tumours.

Gomes PJ, Rustin GJ.

Clin Oncol (R Coll Radiol). 1996;8(6):397-9.

PMID:
8973860
43.

Local anaesthesia for fibreoptic bronchoscopy: comparison between intratracheal cocaine and lignocaine.

Teale C, Gomes PJ, Muers MF, Pearson SB.

Respir Med. 1990 Sep;84(5):407-8.

PMID:
2247670

Supplemental Content

Loading ...
Support Center